Sinovac vaccine meets study goal; shares jump 60 percent

By Vrinda Manocha (Reuters) – China-based Sinovac Biotech Ltd said a late-stage trial of its experimental vaccine for hand, foot and mouth disease (HFMD) met the main study goal of preventing the infection in infants between the ages of 6 months and 35 months. The Sinovac stock jumped as much as 60 percent in early trading, making it the top percentage gainer on the Nasdaq. About 5 million shares changed hands by 1041 ET, nearly 85 times their 10-day average volumes. The trial results showed an immune response to the infection in 95.4 percent of vaccinated subjects. …